Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New inhaled treatment tested for stubborn lung bug

NCT ID NCT06585020

Summary

This study is testing whether adding an inhaled antibiotic called ARIKAYCE® to standard oral drugs works better for treating Mycobacterium xenopi lung infections. It will involve 190 adults with this specific infection to see if the inhaled medicine helps clear the bacteria from the lungs faster and improves outcomes. The goal is to find a more effective and potentially less toxic treatment option for this difficult condition.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG DISEASES are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU Amiens-Picardie

    RECRUITING

    Amiens, 80054, France

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.